Doravirine/islatravir (Idvynso) vs Rilpivirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Doravirine/islatravir (Idvynso)
Marketed by Merck & Co.
NCT05631093 · Phase 3 · active, not recruiting
Trial 051 randomized 551 virologically suppressed adults with HIV-1 2:1, open-label, to switch to once-daily doravirine/islatravir or stay on their baseline antiretroviral regimen. The primary efficacy endpoint was the proportion with HIV-1 RNA at or above 50 copies/mL at Week 48, tested for non-inferiority with a 4-percentage-point margin. The rate was 1.4% after the switch and 4.9% on baseline therapy (difference -3.58, 95% CI -7.81 to -0.77), so non-inferiority was shown and the primary endpoint was met. The other registered primaries are adverse-event rates. Source: ClinicalTrials.gov posted results and the IDVYNSO US label, section 14.
Next expected readout: May 2029 · NCT04776252 (registry estimate)
Reported efficacy
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48; Percentage of Participants Who Experience Adverse Events (AEs) Through Week 48; Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). (met)
Result source: NCT05630755
Rilpivirine · Edurant
Marketed by Johnson & Johnson
NCT00540449 · Phase 3 · completed
This was a large (690-participant), randomized, quadruple-blinded, active-controlled (efavirenz) phase 3 trial with a hard clinical endpoint (confirmed viral load <50 copies/mL). The pre-specified non-inferiority margin was clearly met, with the confidence interval for the treatment difference falling entirely within the allowed -12% boundary, so rilpivirine was shown to be as effective as efavirenz on the primary measure despite a somewhat higher rate of virologic failure and resistance emergence as a secondary finding.
Next expected readout: December 2028 · NCT07637877 (registry estimate)
Reported efficacy
Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%. (met)
Result source: NCT00540449
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Doravirine/islatravir (Idvynso) | Rilpivirine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Trial running · NCT05630755 | 94% vs 94%vs CARNCT0242279712 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT05630755 | 0.6% vs 1%vs FTC/RPV/TDFNCT023452523 other results
|
| CD4 count, change (week 48) | —Trial running · NCT05630755 | 28 vs 18.4vs CARNCT0242279714 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
- Rilpivirine
- 94% vs 94%vs CARNCT02422797
12 other results
- 95% vs 96% NCT02429791
- 93.7% vs 93.9% NCT02345252
- 90% vs 92% NCT02345226
- 85.8% vs 81.6% NCT01309243
- 93.7% vs 89.9% NCT01252940
- 97% vs 98% NCT02422797
- 89.2% vs 88.5% NCT02345252
- 85.2% vs 85.1% NCT02345226
- 77.9% vs 72.4% NCT01309243
- 93.9% vs 96.2% NCT01709084
- 89.3% vs 92.1% NCT01252940
- 98% vs 96% NCT02429791
HIV-1 RNA 50 copies/mL or more (week 48)
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
- Rilpivirine
- 0.6% vs 1%vs FTC/RPV/TDFNCT02345252
3 other results
- 0.7% vs 0.9% NCT02345226
- 0.6% vs 0% NCT02345252
- 1.1% vs 0.9% NCT02345226
CD4 count, change (week 48)
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
- Rilpivirine
- 28 vs 18.4vs CARNCT02422797
14 other results
- 42 vs 42.4 NCT02422797
- 12 vs 16 NCT02345252
- 12 vs 6 NCT02345226
- 278 vs 259 NCT01309243
- 32.3 vs 41.8 NCT02429791
- 9 vs -1 NCT02345252
- 23 vs 12 NCT02345226
- 10 vs -7 NCT01252940
- 200 vs 191 NCT01309243
- 16.2 vs 47.4 NCT02429791
- 20 vs 32 NCT01252940
- 145.9 vs 159.8 NCT00110305
- 158.9 vs 159.8 NCT00110305
- 172 vs 159.8 NCT00110305
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Doravirine/islatravir (Idvynso): 0 of 4 rows · Rilpivirine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Rilpivirine |
|---|---|
| Dropout rate | 24.3%a NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 32 more results20% NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 5.2%DTG + RPV NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Continuation Phase) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early + Late Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 6.1%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 7.5% NCT01709084 · Phase 3 · registry result, not featured evidence 22.3%RPV (TMC278-TiDP6-C209 [C209] and NCT01266902 · Phase 3 · registry result, not featured evidence 25.2%Rilpivirine (RPV) (TMC278-C204 [C2 NCT01266902 · Phase 3 · registry result, not featured evidence 12.7%FTC/RPV/TAF NCT02345252 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence 15.7%FTC/RPV/TAF NCT02345226 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From EFV/FT NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345226 · Phase 3 · registry result, not featured evidence 8.1% NCT01252940 · Phase 3 · registry result, not featured evidence 21% NCT01309243 · Phase 3 · registry result, not featured evidence 0% NCT04012931 · Phase 2 · registry result, not featured evidence 30.6%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 40%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 33.3%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%15 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%12.5 mg NCT00799864 · Phase 2 · registry result, not featured evidence 12.1% NCT02165202 · Phase 2 · registry result, not featured evidence 4% NCT01286740 · Phase 2 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence 7.1% NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 3.5%a NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 32 more results5.3% NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 2.4%DTG + RPV NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Continuation Phase) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early + Late Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 4.2%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT01709084 · Phase 3 · registry result, not featured evidence 3%RPV (TMC278-TiDP6-C209 [C209] and NCT01266902 · Phase 3 · registry result, not featured evidence 2.5%Rilpivirine (RPV) (TMC278-C204 [C2 NCT01266902 · Phase 3 · registry result, not featured evidence 0.6%FTC/RPV/TAF NCT02345252 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence 1.1%FTC/RPV/TAF NCT02345226 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From EFV/FT NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345226 · Phase 3 · registry result, not featured evidence 0.9% NCT01252940 · Phase 3 · registry result, not featured evidence 3% NCT01309243 · Phase 3 · registry result, not featured evidence — NCT04012931 · Phase 2 · registry result, not featured evidence —25 mg NCT00799864 · Phase 2 · registry result, not featured evidence —25 mg NCT00799864 · Phase 2 · registry result, not featured evidence —25 mg NCT00799864 · Phase 2 · registry result, not featured evidence —15 mg NCT00799864 · Phase 2 · registry result, not featured evidence —12.5 mg NCT00799864 · Phase 2 · registry result, not featured evidence — NCT02165202 · Phase 2 · registry result, not featured evidence — NCT01286740 · Phase 2 · registry result, not featured evidence —50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence — NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 11.6%a NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 32 more results9.4% NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 —DTG + RPV NCT02429791 · Phase 3 · registry result, not featured evidence · combination 3.2%DTG + RPV (Continuation Phase) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 13.5%DTG + RPV (Early + Late Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 4%DTG + RPV (Early Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 5.8%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 14.6%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 7.3%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 7.5% NCT01709084 · Phase 3 · registry result, not featured evidence 4.4%RPV (TMC278-TiDP6-C209 [C209] and NCT01266902 · Phase 3 · registry result, not featured evidence 7.6%Rilpivirine (RPV) (TMC278-C204 [C2 NCT01266902 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF NCT02345252 · Phase 3 · registry result, not featured evidence 11.4%FTC/RPV/TAF (Double-Blind Phase) NCT02345252 · Phase 3 · registry result, not featured evidence 5.3%Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence 0%Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF NCT02345226 · Phase 3 · registry result, not featured evidence 12.3%FTC/RPV/TAF (Double-Blind Phase) NCT02345226 · Phase 3 · registry result, not featured evidence 4.8%Open-Label FTC/RPV/TAF From EFV/FT NCT02345226 · Phase 3 · registry result, not featured evidence 0%Open-Label FTC/RPV/TAF From FTC/RP NCT02345226 · Phase 3 · registry result, not featured evidence 6.6% NCT01252940 · Phase 3 · registry result, not featured evidence 9.1% NCT01309243 · Phase 3 · registry result, not featured evidence 0% NCT04012931 · Phase 2 · registry result, not featured evidence 16.7%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%15 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%12.5 mg NCT00799864 · Phase 2 · registry result, not featured evidence 4.4% NCT02165202 · Phase 2 · registry result, not featured evidence 2% NCT01286740 · Phase 2 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence 0% NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a upper respiratory tract infection 15.3% diarrhoea 14.7% headache 14.5% NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 28 more resultsarthralgia 0% back pain 0% bronchitis 0% NCT02429791 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 20.6% headache 14.7% diarrhoea 13.9% NCT02429791 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.7% headache 9.5% diarrhoea 8.7% NCT02429791 · Phase 3 · registry result, not featured evidence · combination DTG 50 mg + RPV 25 mg arthralgia 0% asthenia 0% back pain 0% NCT02422797 · Phase 3 · registry result, not featured evidence · combination DTG 50 mg + RPV 25 mg nasopharyngitis 18.4% upper respiratory tract infection 14.2% bronchitis 10.7% NCT02422797 · Phase 3 · registry result, not featured evidence · combination DTG 50 mg + RPV 25 mg nasopharyngitis 8% upper respiratory tract infection 7.3% arthralgia 6.5% NCT02422797 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 29.6% headache 17.8% urinary tract infection 13.6% NCT01709084 · Phase 3 · registry result, not featured evidence pregnancy 1.9% headache 1.1% alanine aminotransferase increased 0.8% NCT01266902 · Phase 3 · registry result, not featured evidence facial wasting 1.7% hepatitis c 1.7% hypertension 1.7% NCT01266902 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.5% upper respiratory tract infection 14.9% diarrhoea 10.8% NCT02345252 · Phase 3 · registry result, not featured evidence back pain 10.5% conjunctivitis allergic 10.5% cough 10.5% NCT02345252 · Phase 3 · registry result, not featured evidence cough 17.6% nasopharyngitis 17.6% pyrexia 17.6% NCT02345252 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 16.9% nasopharyngitis 11.6% cough 10.3% NCT02345226 · Phase 3 · registry result, not featured evidence rhinitis 16% nasopharyngitis 12% bronchitis 8% NCT02345226 · Phase 3 · registry result, not featured evidence nasopharyngitis 11% diarrhoea 10.7% headache 9.8% NCT01252940 · Phase 3 · registry result, not featured evidence diarrhoea 17.5% nausea 16.5% upper respiratory tract infection 14.5% NCT01309243 · Phase 3 · registry result, not featured evidence vomiting 15.4% alanine aminotransferase increased 11.5% abdominal pain 7.7% NCT04012931 · Phase 2 · registry result, not featured evidence 25 mg upper respiratory tract infection 55.6% influenza 41.7% cough 27.8% NCT00799864 · Phase 2 · registry result, not featured evidence 25 mg upper respiratory tract infection 60% toothache 40% alanine aminotransferase increased 20% NCT00799864 · Phase 2 · registry result, not featured evidence 25 mg upper respiratory tract infection 55.6% decreased appetite 22.2% diarrhoea 22.2% NCT00799864 · Phase 2 · registry result, not featured evidence 15 mg upper respiratory tract infection 100% anaemia 50% dermatitis atopic 50% NCT00799864 · Phase 2 · registry result, not featured evidence 12.5 mg upper respiratory tract infection 100% cough 50% lower respiratory tract infection 50% NCT00799864 · Phase 2 · registry result, not featured evidence injection site pain 75% (placebo 40.5%) injection site pruritus 36.3% (placebo 11.9%) injection site swelling 36.3% (placebo 7.1%) NCT02165202 · Phase 2 · registry result, not featured evidence diarrhoea 16.3% upper respiratory tract infection 14.3% insomnia 12.2% NCT01286740 · Phase 2 · registry result, not featured evidence 50mg/25mg headache 6.3% vessel puncture site bruise 6.3% vomiting 6.3% NCT03984838 · Phase 1 · registry result, not featured evidence insomnia 23.1% NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 31 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Rilpivirine
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 12 more results
show 14 more results
+ 22 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Doravirine/islatravir (Idvynso)'s landscape · Rilpivirine's landscape